To describe the clinical outcomes and potential of xeligekimab in two patients with refractory generalized pustular psoriasis (GPP).
Key Findings:
Both patients exhibited rapid and significant clinical improvement within 3-4 days after a single dose of xeligekimab.
One patient remained in remission at the 3-month follow-up after only one injection.
Xeligekimab was well-tolerated with no reported adverse events.
Interpretation:
This case study suggests that xeligekimab may be a potent therapeutic option for inducing rapid and sustained remission in patients with refractory GPP, warranting further investigation.
Limitations:
The study is based on only two case reports, limiting generalizability and the ability to draw broader conclusions.
Long-term efficacy and safety of xeligekimab in GPP remain to be established.
Conclusion:
Xeligekimab shows promise as an effective treatment for refractory GPP, warranting further investigation to confirm its efficacy and safety.
